Showing posts with label saccharomyces boulardii. Show all posts
Showing posts with label saccharomyces boulardii. Show all posts

Saturday, 23 July 2016

On probiotics and irritable bowel syndrome (IBS)

Granted, I am taking a slight departure from the material typically discussed on this blog by introducing the paper by Yan Zhang and colleagues [1] who reported the findings of a meta-analysis examining "the efficacy of different probiotic types, doses and treatment durations in IBS [irritable bowel syndrome] patients diagnosed by Rome III criteria via a meta-analysis of randomized controlled trials (RCTs)." The results however - "Probiotics are an effective pharmacological therapy in IBS patients" - were important enough for me to think about discussing, particularly in the context that IBS might not be stand-alone condition (see here) and some recent research in progress [2] (see here for my take) that could illustrate some wider relevance.

The Zhang paper is open-access so doesn't need any grand rewriting from me in terms of methods or findings but a few things stick out. First is the fact that quite a few different probiotic preparations have been experimentally examined with IBS in mind. From the 21 studies looked at by Zhang et al, we have some recurring themes including different types of Lactobacillus acidophilus and Lactobacillus rhamnosus for example being included in the preparations. The inclusion of a preparation called VSL#3 also caught me eye in light of some discussions about a potential 'antibiotic brain' recently on this blog (see here) and what might reverse this in mice. Of additional note was the use of an old friend: Saccharomyces boulardii that continues to impress [3].

Second, and related to the first point, are the authors conclusions that: "Single probiotics, a low dose, and a short treatment duration were more effective with respect to overall symptom response and QoL [quality of life]." The authors provide some rather interesting forest plots illustrating how the analysed data helped them reach this conclusion; albeit bearing in mind that "the effects of individual probiotic species" were not analysed in the current meta-analysis. In other words, some preparations seem to work pretty well but we don't know enough about which ones used under which circumstances.

Finally, I noted that the whilst the use of a placebo was an important eligibility criteria for inclusion in their meta-analysis - "the studies were randomized controlled trials (RCTs) that compared probiotics with placebo" - the authors did not shy away from the fact that: "An appreciable placebo effect was detected in some studies, which may have minimized the effects of probiotics." Placebo effects and IBS is something again, that has been discussed before on this blog (see here) bearing in mind I'm not saying that IBS is 'all in the mind' or anything like that.

Set within the context of other recent meta-analyses concluding that: "There were alterations of gut microbiota in IBS patients and it implied that alterations of gut microbiota might be involved in the pathogenesis of IBS" [4] one shouldn't necessarily be surprised that there may have been effects from the use of probiotics in cases of IBS. Assuming that an oral probiotic is able to survive the stomach environment and actually colonise [parts of] the gastrointestinal (GI) tract (if only for a defined amount of time) the cost-effectiveness of this intervention coupled with the low rates of side-effects makes for impressive reading in terms of the treatment of at least some cases of IBS.

----------

[1] Zhang Y. et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterology. 2016; 16: 62.

[2] Santocchi E. et al. Gut to brain interaction in Autism Spectrum Disorders: a randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters. BMC Psychiatry. 2016 Jun 4;16:183.

[3] Szajewska H. & Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2015 Oct;42(7):793-801.

[4] Zhuang X. et al. Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016 Jun 14.

----------

ResearchBlogging.org Zhang Y, Li L, Guo C, Mu D, Feng B, Zuo X, & Li Y (2016). Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC gastroenterology, 16 (1) PMID: 27296254

Tuesday, 14 June 2011

Purine metabolism and autism

Autism is replete with different areas of research and investigation. Trends in the various lines of inquiry taken down the years have tended to coincide with the various scientific 'fashions' of the times. Outside of the more psychological themes, there was in the early days up to the mid-1990's, research which seemed to be very heavily biochemistry-focused in autism. Serotonin, dopamine, endorphins and enkephalins and other like-minded compounds took centre stage in the era of biological psychiatry. The brain (and its chemical minions) was King.

Then began the era of genetics which jumped with a loud 'ta-da' onto the autism research stage. The initial mapping of the human genome was the impetus and all and everything was about genes. It initially started with the various population-wide studies of genes, moving in later years to the realisation that autism, like many conditions, is not a 'single gene condition'. Increased interest in the various descriptions of the broader autism phenotype, together with advancing technology, heralded the age of SNPs and CNVs into autism research. Genes were King.

At the current time, I think we are evolving again; currently being in the process of another shift in the research paradigm, with the onset of epigenetics and gene-environment interactions. 'We are all a consequence of our genes and environment' - or so the fashion tells. Certainly the conclusions from many studies seem to be heading in that direction. The brain, genes and environment all sit on the same throne.

For this post I am venturing back a few years to those olden' days of biochemistry and autism, and in particular, research on purine metabolism in relation to autism. Mary Coleman was a main player in purine research in autism. She was no stranger to autism research by any means and credited with some very interesting (and early) observations including the suggestion that about a quarter of people with autism also presented with a co-morbid defined medical disorder.

To the post at hand. What are purines? Stand-by for biochemistry 101. There is quite a complex description of purines here. Basically purines are a class of compound which all share two particular details in their chemical structure called a pyrimidine ring and imidazole ring. Pyrimidines and purines are of some interest to geneticists generally because the nucleotides which form our DNA [(A)denine, (G)uanine, (C)ytosine, (T)hymine] are pyrimidines (C & T) and purines (A & G). Aside from forming the base nucleotides, purines have quite a few other roles to play body-wide, notably in relation to things like ATP as a main energy source for cells.

Purines have been of some interest to autism for a while. The connection between purines and autism seems to have been predominantly due to the excessive excretion of a particular purine, uric acid, reported by some authors (including Coleman). Many people might have heard about uric acid in relation to conditions such as gout (one of the 'many' diseases suggested to be carried by King 'Enry VIII) but there are quite a few other conditions potentially connected to elevated levels of uric acid. Coleman and colleagues estimated that about 20% of people with autism might present with elevated uric acid levels (hyperuricosuria) although whether this is co-morbidity or specifically tied into presented symptoms is unclear. There is a case report by Ted Page (who worked with Coleman) suggesting that treatment with uridine correlated with positive changes to presented autistic symptoms, with regression when treatment was halted. This was followed up by a small trial (n=9) where benefits were noted up to 8 years later. Interestingly, uridine is found in quite a few foods including brewer's yeast (saccharomyces cerevisiae) - a cousin (but not the same as) of our old friend saccharomyces boulardii.

As per my previous disclaimers, I am not suggesting that uridine or brewer's yeast in this context is in any way, shape or form an 'intervention' option for autism or anything else. The Page papers, whilst interesting, reported on only small participant numbers and as far as I can see no-one has yet done anything further on this issue to decide whether raised uric acid levels are a chance finding or if not just epiphenomenal. It is therefore difficult to ascertain proper safety or efficacy data in this area; an area which seems to have gone the same way as the sulphate (sulfate) research.

Tuesday, 19 April 2011

Saccharomyces boulardii - Nescio quid dicas

Science is literally 'littered' with words and phrases in Latin. With a rudimentary knowledge of Latin (and Greek) I am sure that much of the 'fog' around Science would lift in an instant for many people. The title of this post says two things: saccharomyces boulardii which I will come to shortly, and the words 'I don't know what you are talking about' (I hope).

I have wanted to talk about saccharomyces boulardii for a while now for several reasons. Not only is it one of the coolest names for anything in Science, but this relatively modest yeast seems to have some surprising properties which might just tie into quite a few things I have blogged about previously.

S. boulardii (to those in the know!) is a handy little yeast which has been applied to a few conditions most of which have some connection to the gut or gastrointestinal problems. Diarrhoea (diarrhea), whether caused by things like certain Clostridia species or following the use of anti-microbials, has been a target of S. boulardii.  The evidence for effect, measured by randomised-controlled blinded trials, in these areas is actually quite impressive. There is also some suggestion that s.boulardii might be quite effective in managing certain types of inflammatory bowel disease such as ulcerative colitis and might have a beneficial effect on certain types of gut bacteria outside of Clostridia.

The discerning reader of this blog can perhaps see where I am going with this in relation to autism and the GI co-morbidity and gut bacteria issues present in some cases. Indeed, S. boulardii has been mentioned briefly in the research literature with regards to autism, combined with quite a few anecdotal reports scattered around the Internet about its possible usefulness (note, I am making no formal recommendations at this point).

How and why it works is another matter.

There is some speculation that S.boulardii might have more than one effect: anti-microbial, anti-inflammatory, etc.  One quite interesting possibility, specifically in relation to autism and the findings of reduced dissacharidase activity reported recently, is the suggestion that S.boulardii might increase such enzyme activity (at least in the rat model).

So there you have it. Saccharomyces boulardii, a simple yeast seemingly punching well above its weight. A bit of a John McClane character. Dic mihi solum facta, domina (translation: 'just the facts ma'am')